Geode Capital Management LLC Buys 19,136 Shares of INmune Bio, Inc. (NASDAQ:INMB)

Geode Capital Management LLC lifted its stake in shares of INmune Bio, Inc. (NASDAQ:INMB) by 5.6% in the fourth quarter, HoldingsChannel reports. The fund owned 363,602 shares of the company’s stock after acquiring an additional 19,136 shares during the period. Geode Capital Management LLC’s holdings in INmune Bio were worth $1,698,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. JPMorgan Chase & Co. grew its stake in INmune Bio by 93.0% during the fourth quarter. JPMorgan Chase & Co. now owns 11,335 shares of the company’s stock valued at $53,000 after acquiring an additional 5,461 shares in the last quarter. Jane Street Group LLC purchased a new position in shares of INmune Bio during the third quarter valued at about $79,000. Financial Advocates Investment Management increased its holdings in shares of INmune Bio by 14.8% in the fourth quarter. Financial Advocates Investment Management now owns 15,500 shares of the company’s stock worth $72,000 after purchasing an additional 2,000 shares during the last quarter. Rhumbline Advisers lifted its position in shares of INmune Bio by 16.9% in the fourth quarter. Rhumbline Advisers now owns 16,744 shares of the company’s stock worth $78,000 after buying an additional 2,424 shares in the last quarter. Finally, LPL Financial LLC boosted its stake in INmune Bio by 33.0% during the fourth quarter. LPL Financial LLC now owns 19,072 shares of the company’s stock valued at $89,000 after buying an additional 4,730 shares during the last quarter. 12.72% of the stock is owned by hedge funds and other institutional investors.

INmune Bio Price Performance

INmune Bio stock opened at $7.85 on Wednesday. INmune Bio, Inc. has a 12 month low of $4.32 and a 12 month high of $12.72. The stock has a market capitalization of $180.42 million, a PE ratio of -3.60 and a beta of 1.86. The business has a 50 day simple moving average of $7.78 and a 200-day simple moving average of $6.74.

INmune Bio (NASDAQ:INMB) last posted its quarterly earnings data on Thursday, March 27th. The company reported ($0.40) EPS for the quarter, beating the consensus estimate of ($0.54) by $0.14. On average, equities research analysts anticipate that INmune Bio, Inc. will post -2.24 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have commented on the stock. Maxim Group lifted their price objective on shares of INmune Bio from $22.00 to $30.00 and gave the stock a “buy” rating in a research note on Thursday, February 13th. RODMAN&RENSHAW upgraded shares of INmune Bio to a “strong-buy” rating in a report on Tuesday, January 28th. Rodman & Renshaw initiated coverage on INmune Bio in a research report on Tuesday, January 28th. They set a “buy” rating and a $23.00 target price for the company. Finally, Scotiabank increased their price target on INmune Bio from $22.00 to $23.00 and gave the stock a “sector outperform” rating in a report on Tuesday, February 11th. Five equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, INmune Bio currently has an average rating of “Buy” and a consensus price target of $22.80.

INmune Bio Company Profile

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.